Grufity logoGrufity logo

BMRN

97.79USD+6.61(+7.25%)Market Closed

Biomarin Pharmaceutical Inc

Market Summary

USD97.79+6.61Market Closed
7.25%

BMRN Alerts

BMRN Stock Price

RSI Chart

Valuation

Market Cap

16.1B

Price/Earnings

192.15

Price/Sales

8.03

Price/Cashflow

89.43

MarketCap/EBT

160.34

Price/Sales

Profitability

Operating Margin

76.29%

EBT Margin

5.01%

Return on Equity

1.84%

Return on Assets

1.34%

Fundamentals

Revenue

Revenue (TTM)

2.0B

Revenue Y/Y

23.63%

Revenue Q/Q

-5.33%

Earnings

Earnings (TTM)

83.9M

Earnings Y/Y

81.77%

Earnings Q/Q

-124.05%

Price Action

52 Week Range

70.7399.74
(Low)(High)

Last 7 days

13.9%

Last 30 days

8.8%

Last 90 days

4.8%

Trailing 12 Months

8.9%

Financial Health

Current Ratio

5.15

Investor Care

Shares Dilution (1Y)

1.23%

Diluted EPS (TTM)

0.42

Peers (Alternatives to Biomarin Pharmaceutical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
9.20% 42.94%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
23.80% 26.69%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
32.92% -36.03%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
10.50% 19.40%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
8.05% 36.62%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
9.46% -34.45%
-12.87
32.5
-41.50% -607.58%
3.4B
-
4.94% -44.70%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
3.91% -62.35%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
-2.27% -43.94%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-18.16% -91.52%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-14.16% -78.53%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
9.64% -40.39%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-17.25% -60.25%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-21.78% -90.28%
-13.56
44.06
522.71% -129.91%
218.9M
-
-19.25% -80.88%
-2.36
609.63
-71.03% -64.56%

Financials for Biomarin Pharmaceutical

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue5.1%2,0081,9121,8801,8461,849
Cost Of Revenue2.8%476463467471477
  S&GA Expenses4.2%826792780759737
  R&D Expenses0.0%638638641629624
Earnings Before Taxes78.6%1015636-75.35-48.96
Net Income55.2%845439-64.0816
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.9%6,2646,1466,0636,0035,977
  Current Assets6.6%2,6832,5182,3942,2742,312
    Cash Equivalents22.9%762620605587617
  Inventory4.6%839802786777749
  Net PPE0.2%1,0521,0491,0401,0351,025
  Goodwill0%196196196196196
Liabilities3.3%1,6961,6411,6711,7331,711
  Current Liabilities12.1%521465490540515
Shareholder's Equity1.4%4,5694,5054,3914,2714,266
  Retained Earnings-1.5%-788.95-777.23-804.89-925.69-867.79
  Additional Paid-In Capital1.2%5,3365,2735,2065,1925,134
Accumulated Depreciation2.7%782762741721700
Shares Outstanding0.2%186185185184184
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations51.5%180119146305280
  Share Based Compensation3.0%193188196197201
Cashflow From Investing82.3%-20.74-117.18-207.74-366.31-299.86
Cashflow From Financing36.2%-15.12-23.69-0.96-0.05-380.60
  Buy BacksNaN%00
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on BMRN?

64.2%


Probability that Biomarin Pharmaceutical stock will be more than 20% underwater in next one year

30%


Probability that Biomarin Pharmaceutical stock will be more than 30% underwater in next one year.

18.5%


Probability that Biomarin Pharmaceutical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BMRN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Biomarin Pharmaceutical was unfortunately bought at previous high price.

Returns

Cumulative Returns on BMRN

7.1%


10-Year Cumulative Returns

0.3%


7-Year Cumulative Returns

3.4%


5-Year Cumulative Returns

7.9%


3-Year Cumulative Returns

What are the long-term rolling returns for BMRN?

FIve years rolling returns for Biomarin Pharmaceutical.

Which funds bought or sold BMRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
5.96
33,000
428,000
0.02%
2022-11-22
Mint Tower Capital Management B.V.
NEW
-
1,356,000
1,356,000
0.10%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
11,823,000
11,823,000
0.14%
2022-11-22
CVA Family Office, LLC
UNCHANGED
-
-
5,000
-%
2022-11-21
FourThought Financial, LLC
ADDED
171.61
23,000
36,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.89
347,000
25,528,000
0.04%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
-
9,000
-%
2022-11-18
Industrial Alliance Investment Management Inc.
ADDED
4.51
257,000
3,989,000
0.12%
2022-11-18
National Pension Service
REDUCED
-9.37
-1,781,000
23,768,000
0.05%
2022-11-17
M&T Bank Corp
REDUCED
-3.64
6,000
552,000
-%

1–10 of 42

Latest Funds Activity

Are funds buying BMRN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own BMRN

Biomarin Pharmaceutical News

Seeking Alpha

Hot Stocks: Movie theater chains rally; YMM jumps on earnings; PAGS falls.23 hours ago

BMRN Fair Value

Recent SEC filings of Biomarin Pharmaceutical

View All Filings
Date Filed Form Type Document
Nov 04, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Nov 01, 2022
4
Insider Trading
Oct 28, 2022
10-Q
Quarterly Report
Oct 26, 2022
8-K
Current Report
Oct 18, 2022
4
Insider Trading
Oct 07, 2022
8-K
Current Report
Sep 12, 2022
8-K
Current Report
Aug 16, 2022
4
Insider Trading

Latest Insider Trading transactions for BMRN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-02
Ajer Jeffrey Robert
SOLD
-258,360
86.12
-3,000
EVP, Chief Commercial Officer
2022-10-31
Alles Mark J
BOUGHT
314,469
86.75
3,625
-
2022-10-31
BIENAIME JEAN JACQUES
SOLD
-129,825
86.55
-1,500
Chief Executive Officer
2022-10-14
BIENAIME JEAN JACQUES
SOLD
-359,560
89.89
-4,000
Chief Executive Officer
2022-08-15
BIENAIME JEAN JACQUES
SOLD
-285,630
95.21
-3,000
Chief Executive Officer
2022-08-12
BIENAIME JEAN JACQUES
SOLD
-379,000
94.75
-4,000
Chief Executive Officer
2022-08-11
Ajer Jeffrey Robert
SOLD
-286,860
95.62
-3,000
EVP, Chief Commercial Officer
2022-08-09
Davis George Eric
SOLD
-4,914,660
95.9595
-51,216
EVP, Chief Legal Officer
2022-08-09
Davis George Eric
ACQUIRED
3,222,740
67.81
47,526
EVP, Chief Legal Officer
2022-08-08
Guyer Charles Greg
SOLD
-599,155
96.56
-6,205
EVP, Chief Technical Officer

1–10 of 50

Jean-Jacques Bienaimé
3040
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BMRN Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
REVENUES:    
Total revenues$ 505,344$ 408,742$ 1,558,501$ 1,396,465
OPERATING EXPENSES:    
Cost of sales116,288103,537356,379350,765
Research and development157,829157,869476,855467,701
Selling, general and administrative216,816183,333608,270541,812
Intangible asset amortization and contingent consideration16,82817,22250,93552,648
Gain on sale of nonfinancial assets, net00(108,000)0
Total operating expenses507,761461,9611,384,4391,412,926
INCOME (LOSS) FROM OPERATIONS(2,417)(53,219)174,062(16,461)
Interest income4,9991,8279,3248,737
Interest expense(4,679)(3,870)(12,344)(11,491)
Other income (expense), net1939,102(3,908)10,439
INCOME (LOSS) BEFORE INCOME TAXES(1,904)(46,160)167,134(8,776)
Provision for (benefit from) income taxes4,748(9,666)25,324(2,594)
NET INCOME (LOSS)$ (6,652)$ (36,494)$ 141,810$ (6,182)
NET INCOME (LOSS) PER SHARE, BASIC (in dollars per share)$ (0.04)$ (0.20)$ 0.77$ (0.03)
NET INCOME (LOSS) PER SHARE, DILUTED (in dollars per share)$ (0.04)$ (0.20)$ 0.75$ (0.03)
Weighted average common shares outstanding, basic (in shares)185,597183,214185,009182,616
Weighted average common shares outstanding, diluted (in shares)185,597183,214192,252182,616
COMPREHENSIVE INCOME (LOSS)$ 5,625$ (25,316)$ 158,127$ 20,196
Net product revenues    
REVENUES:    
Total revenues493,348393,8401,516,5331,348,279
Royalty and other revenues    
REVENUES:    
Total revenues$ 11,996$ 14,902$ 41,968$ 48,186

BMRN Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
[1]
Current assets:  
Cash and cash equivalents$ 761,515$ 587,276
Short-term investments512,253426,599
Accounts receivable, net419,622373,399
Inventory839,460776,669
Other current assets149,851110,442
Total current assets2,682,7012,274,385
Noncurrent assets:  
Long-term investments372,302507,793
Property, plant and equipment, net1,051,8211,035,461
Intangible assets, net354,024388,652
Goodwill196,199196,199
Deferred tax assets1,455,2051,450,161
Other assets151,788152,121
Total assets6,264,0406,004,772
Current liabilities:  
Accounts payable and accrued liabilities492,717498,265
Short-term contingent consideration28,30348,232
Total current liabilities521,020546,497
Noncurrent liabilities:  
Long-term convertible debt, net1,082,0331,079,077
Long-term contingent consideration015,167
Other long-term liabilities92,47398,361
Total liabilities1,695,5261,739,102
Stockholders’ equity:  
Common stock, $0.001 par value: 500,000,000 shares authorized; 185,824,253 and 183,912,514 shares issued and outstanding, respectively186184
Additional paid-in capital5,335,8535,191,502
Company common stock held by the Nonqualified Deferred Compensation Plan(9,325)(9,689)
Accumulated other comprehensive income30,74914,432
Accumulated deficit(788,949)(930,759)
Total stockholders’ equity4,568,5144,265,670
Total liabilities and stockholders’ equity$ 6,264,040$ 6,004,772
[1](1)Certain December 31, 2021 balances have been corrected for an immaterial error identified in the third quarter of 2022. See Note 1 to these Condensed Consolidated Financial Statements for details.